(KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicentric phase II study. J Clin
Oncol 30:837–842. https://doi.org/10.1200/JCO.2011.37.3472
Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bending MM (1991) Humanization of a
mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop
conformation. Protein Eng 4:773–783. https://doi.org/10.1093/protein/4.7.773
Köhler G, Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined
specificity. Nature 256:495–497. https://doi.org/10.1038/256495a0
Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC,
Mashayekh R, Wymore K, Mclabe JG et al (1994) Antigen-specific human antibodies from
mice comprising four distinct genetic modifications. Nature 368:856–859. https://doi.org/10.
1038/368856a0
Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kndo H, Umetsu M, Sone Y, Asano R, Kumagai I
(2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized
anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283:1156–
1166. https://doi.org/10.1074/jbc.M706190200
Morrison SL, Johnson MJ, Herzenberg LA, Qi VT (1984) Chimeric human antibody molecules:
mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S
A 81:6851–6855. https://doi.org/10.1073/pnas.81.21.6851
Navarra SV, Guzman RM, Gallacher AE, Hal S, Levy RA, Jimenez RE, Li EK-M, Thomas M, Kim
H-Y, Leon MG et al (2011) Efficacy and safety of belimumab in patients with active systemic
lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 377:721–731.
https://doi.org/10.1016/S0140-6736(10)61354-2
Neuberger MS, Milstein C (1995) Somatic hypermutation. Curr Opin Immunol 7:248–254. https://
doi.org/10.1016/0952-7915(95)80010-7
Newman MJ, Benani DJ (2016) A review of blinatumomab, a novel immunotherapy. J Oncol
Pharm Pract 22:639–645. https://doi.org/10.1177/1078155215618770
Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hare M, Kolodziej S, Mitsuda Y,
Gonzolez V, Sait RB et al (2015) Specific amyloid β clearance by a catalytic antibody construct.
J Biol Chem 290:10229–10241. https://doi.org/10.1074/jbc.M115.641738
Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardiev PM (1993) Humani-
zation of an antibody directed against IgE. J Immunol 151:2623–2632
Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy.
Nature 332:323–327. https://doi.org/10.1038/332323a0
Seimetz D (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody
catumaxomab (Removab®). J Cancer 2:309–316. https://doi.org/10.7150/jca.2.309
Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to
multiple injections of murine monoclonal IgG. J Immunol 2:1530–1535
Shearman CW, Pollock D, White G, Hehir K, Moore GP, Kenzy EJ, Kurrle R (1991) Construction,
expression and characterization of humanized antibodies directed against the human alpha/beta
T cell receptor. J Immunol 147:4366–4373
Skerra A, Pluckthun A (1988) Assembly of a functional immunoglobulin Fv fragment in
Escherichia coli. Science 240:1038–1041. https://doi.org/10.1126/science.3285470
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens
on the virion surface. Science 228:1315–1317. https://doi.org/10.1126/science.4001944
Strube RW, Chen SY (2002) Characterization of anti-cyclin E single chain Fv antibodies and
intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J
Immunol Methods 263:149–167. https://doi.org/10.1016/s0022-1759(02)00035-2
Tan P, Mitchell DM, Buss TN, Holmes MA, Anasetti C, Foote J (2002) “Superhumanized”
antibodies: reduction of immunogenic potential by complementarity determining region
grafting with human germline sequences: application to an anti-CD28. J Immunol 169:1119–
1125. https://doi.org/10.4049/jimmunol.162.2.1119
22
Therapeutic Human Monoclonal Antibodies
417